Keywords: Breast, Treatment Response
Motivation: Functional tumor volume (FTV) and background parenchymal enhancement (BPE) are potentially useful MRI markers for assessing HR+/HER2– breast cancer undergoing neoadjuvant endocrine treatment (NET).
Goal(s): We aimed to investigate the combined ability of FTV and BPE as early markers of treatment response to NET, defined by pre-surgery FTV.
Approach: We tested the performance of FTV and BPE available up to 3 weeks of treatment in predicting whether pre-surgery FTV is more than or less than 1.1 cc.
Results: Both early changes in FTV and BPE predicted pre-surgery FTV and may be more effective when used in combination.
Impact: Functional tumor volume (FTV) and background parenchymal enhancement (BPE) derived from baseline and 3-week MRI predicted the final FTV after neoadjuvant endocrine treatment (NET) for patients with HR+/HER2– breast cancer. These metrics may be non-invasive early markers for NET.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords